Skip to main content

Advertisement

SpringerLink
Log in

Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro

  • Published:
In Vitro Cellular & Developmental Biology - Animal Aims and scope Submit manuscript

Abstract

Tumor heterogeneity may give rise to differential responses to chemotherapy drugs. Therefore, unraveling tumor heterogeneity has an implication for biomarker discovery and cancer therapeutics. To test this phenomenon, we investigated the differential responses of three secondary colorectal cancer cell lines of different origins (HCT116, HT29, and SW620 cells) and four novel primary cell lines obtained from different colorectal cancer patients to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) and explored the differences in gene expression among the primary cell lines in response to exposure to cytotoxic drugs. Cells were exposed to different doses of 5-FU and L-OHP separately or in combinations of equitoxic drug or equimolar drug ratios (median effect of Chou-Talalay principle). Cell viability was assessed using MTT assay and the respective IC50 values were determined. Changes in gene expression in primary cell lines after exposure to the same drug doses were compared using real-time PCR array. The sensitivities (IC50) of different cell lines, both secondary and primary, to 5-FU and L-OHP were significantly different, whether in monotherapy or combined treatment. Primary cell lines needed higher doses to reach IC50. There were variations in gene expression among the primary cell lines of different chemosensitivities to the challenge of the same combined dose of 5-FU and L-OHP. The results confirm the heterogeneous nature of colorectal cancer cells from different patient tumors. Studies using primary cancer cells established from patient’s tumors rather than secondary cell lines will more closely reflect the actual character of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1.

Similar content being viewed by others

References

  • AbuHammad S, Zihlif M (2013) Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics 101(4):213–220

    Article  CAS  PubMed  Google Scholar 

  • Agarwal P, Sandey M, DeInnocentes P, Bird RC (2013) Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer. J Cell Biochem 114(6):1355–1363

    Article  CAS  PubMed  Google Scholar 

  • Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA (2013) Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2:e71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14(6):959–970

    CAS  PubMed  Google Scholar 

  • Altschuler SJ, Wu LF (2010) Cellular heterogeneity: do differences make a difference? Cell 141(4):559–563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Arul M, Roslani AC, Ng CLL, Cheah SH (2014) Culture of low passage colorectal cancer cells and demonstration of variation in selected tumour marker expression. Cytotechnology 66(3):481–491

    Article  CAS  PubMed  Google Scholar 

  • Bijnsdorp IV, Giovannetti E, Peters GJ (2011) Analysis of drug interactions. Methods Mol Biol 731:421–434

    Article  CAS  PubMed  Google Scholar 

  • Boyd LK, Mao X, Lu YJ (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 9(11):652–664

    Article  PubMed  Google Scholar 

  • Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467):338–345

    Article  CAS  PubMed  Google Scholar 

  • Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 22:27–55

    Article  CAS  Google Scholar 

  • Christmann MA, Kaina B (2013) Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res 41(18):8403–8420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF (2007) Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 67(1):398–407

    Article  CAS  PubMed  Google Scholar 

  • De Angelis PM, Svendsrud DH, Kravik KL, Stokke T (2006) Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5:20

    Article  PubMed  PubMed Central  Google Scholar 

  • Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047

    Article  CAS  PubMed  Google Scholar 

  • Douillard JY, Sobrero A, Carnaghi C, Comella P, Diaz-Rubio E, Santoro A, Van Cutsem E (2003) Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 14(Suppl 2):ii7–i12

    PubMed  Google Scholar 

  • Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3(6):e2428

    Article  PubMed  PubMed Central  Google Scholar 

  • Edmondson R, Broglie JJ, Adcock AF, Yang L (2014) Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol 12(4):207–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Failli A, Consolini R, Legitimo A, Spisni R, Castagna M, Romanini A, Crimaldi G, Miccoli P (2009) The challenge of culturing human colorectal tumor cells: establishment of a cell culture model by the comparison of different methodological approaches. Tumori 95(3):343–347

    CAS  PubMed  Google Scholar 

  • Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G (2001) Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 84(4):579–585

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108(3):479–485

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Flis S, Splwinski J (2009) Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res 29(1):435–441

    CAS  PubMed  Google Scholar 

  • Friedlander TW, Fong L (2014) The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol 32(11):1104–1106

    Article  CAS  PubMed  Google Scholar 

  • Garg A, Aggarwal BB (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16(6):1053–1068

    Article  CAS  PubMed  Google Scholar 

  • Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, Savage K, Mackay A, Ashworth A, Reis-Filho JS (2010) Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 220(5):562–573

    Article  CAS  PubMed  Google Scholar 

  • Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147

    Article  CAS  PubMed  Google Scholar 

  • Goodspeed A, Heiser LM, Gray JW, Costello JC (2016) Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res 14(1):3–13

    Article  CAS  PubMed  Google Scholar 

  • Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33(6):565–577

    Article  CAS  PubMed  Google Scholar 

  • Greene BT, Hughes AD, King MR (2012) Circulating tumor cells: the substrate of personalized medicine? Front Oncol 2:69

    Article  PubMed  PubMed Central  Google Scholar 

  • Hato SV, de Vries IJ, Lesterhuis WJ (2012) STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology 1(2):234–236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heppner GH (1984) Tumor heterogeneity. Cancer Res 44(6):2259–2265

    CAS  PubMed  Google Scholar 

  • Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6:1769–1792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnston PG, Kaye S (2001) Capecitabine: a novel agent for the treatment of solid tumors. Anti-Cancer Drugs 12(8):639–646

    Article  CAS  PubMed  Google Scholar 

  • Joyce NC, Harris DL, Zhu CC (2011) Age-related gene response of human corneal endothelium to oxidative stress and DNA damage. Invest Ophthalmol Vis Sci 52(3):1641–1649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y (2012) Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci 9(1):33–39

    Article  CAS  PubMed  Google Scholar 

  • Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB (2003) The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64(2):466–473

    Article  CAS  PubMed  Google Scholar 

  • King RJB, Robins MW (2006) Cancer biology. Pearson Education Limited, England

    Google Scholar 

  • Ku JL, Shin YK, Kim DW, Kim KH, Choi JS, Hong SH, Jeon YK, Kim SH, Kim HS, Park JH, Kim IJ, Park JG (2010) Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis 31(6):1003–1009

    Article  CAS  PubMed  Google Scholar 

  • Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31(2):90–105

    Article  CAS  PubMed  Google Scholar 

  • Lee J-Y, Yoon J-K, Kim B, Kim S, Kim MA, Lim H, Bang D, Song Y-S (2015) Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer 15(1):1–9

    Article  Google Scholar 

  • Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659–666

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lin CC, Lin SY, Chung JG, Lin JP, Chen GW, Kao ST (2006) Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle. Anticancer Res 26(2a):1097–1104

    CAS  PubMed  Google Scholar 

  • Manoochehri M, Karbasi A, Bandehpour M, Kazemi B (2014) Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. Pathol Oncol Res 20(2):301–307

  • Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291–1295

    Article  CAS  PubMed  Google Scholar 

  • Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12(5):323–334

    Article  CAS  PubMed  Google Scholar 

  • Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS (2006) Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5(7):1854–1863

    Article  CAS  PubMed  Google Scholar 

  • Mhaidat NM, Bouklihacene M, Thorne RF (2014) 5-fluorouracil-induced apoptosis in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein kinase C-delta. Oncol Lett 8(2):699–704

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mitra A, Mishra L, Li S (2013) Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol 31(6):347–354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morata-Tarifa C, Jiménez G, García MA, Entrena JM, Griñán-Lisón C, Aguilera M, Picon-Ruiz M, Marchal JA (2016) Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells. Sci Rep 6:18772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nannizzi S, Veal GJ, Giovannetti E, Mey V, Ricciardi S, Ottley CJ, Del Tacca M, Danesi R (2010) Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemother Pharmacol 66(3):547–558

    Article  CAS  PubMed  Google Scholar 

  • Orlowski RZ, Baldwin AS Jr (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8(8):385–389

    Article  CAS  PubMed  Google Scholar 

  • Puig-Butille JA, Escamez MJ, Garcia-Garcia F, Tell-Marti G, Fabra A, Martinez-Santamaria L, Badenas C, Aguilera P, Pevida M, Dopazo J, del Rio M, Puig S (2014) Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget 5(6):1439–1451

    Article  PubMed  Google Scholar 

  • Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS et al (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510–523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, Gazzaniga P (2014) Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol Ther 15(5):496–503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ray S, Langan RC, Mullinax JE, Koizumi T, Xin H-W, Wiegand GW, Anderson AJ, Stojadinovic A, Thorgeirsson S, Rudloff U, Avital I (2012) Establishment of human ultra-low passage colorectal cancer cell lines using spheroids from fresh surgical specimens suitable for in vitro and in vivo studies. J Cancer 3:196–206

    Article  PubMed  PubMed Central  Google Scholar 

  • Rowehl RA, Burke S, Bialkowska AB, Pettet DW III, Rowehl L, Li E, Antoniou E, Zhang Y, Bergamaschi R, Shroyer KR, Ojima I, Botchkina GI (2014) Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cells. PLoS One 9(6):e99091

    Article  PubMed  PubMed Central  Google Scholar 

  • Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10(4):241–253

    Article  CAS  PubMed  Google Scholar 

  • Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512

    Article  CAS  PubMed  Google Scholar 

  • Smith ML, Seo YR (2002) p53 regulation of DNA excision repair pathways. Mutagenesis 17(2):149–156

    Article  CAS  PubMed  Google Scholar 

  • Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91(2):344–354

    CAS  PubMed  PubMed Central  Google Scholar 

  • Toloudi M, Apostolou P, Papasotiriou I (2015) Efficacy of 5-FU or oxaliplatin monotherapy over combination therapy in colorectal cancer. J Cancer Ther 6:345–355

  • Tomida A and T Tsuruo (2001) Drug resistance pathways as targets. In: D. J. K. Bruce C. Baguley (eds) Anticancer drug development. Academic Press

  • Toss A, Mu Z, Fernandez S, Cristofanilli M (2014) CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med 2(11):108

    PubMed  PubMed Central  Google Scholar 

  • Valente MJ, Henrique R, Costa VL, Jeronimo C, Carvalho F, Bastos ML, de Pinho PG, Carvalho M (2011) A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens. PLoS One 6(5):e19337

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Volkova E, Robinson BA, Willis J, Currie MJ, Dachs GU (2014) Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett 7(2):311–320

    PubMed  Google Scholar 

  • Yang K, Hitomi M, Stacey DW (2006a) Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div 1:32

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang YA, Zhang GM, Feigenbaum L, Zhang YE (2006b) Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9(6):445–457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported in part by a University of Malaya Research University grant (no. RG534-13HTM).

Author information

Authors and Affiliations

  1. Department of Physiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia

    Melanie Arul & Swee Hung Cheah

  2. Department of Surgery, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia

    April Camilla Roslani

Authors
  1. Melanie Arul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. April Camilla Roslani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Swee Hung Cheah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Melanie Arul or Swee Hung Cheah.

Additional information

Editor: Tetsuji Okamoto

Electronic supplementary material

.

ESM 1

(DOCX 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arul, M., Roslani, A.C. & Cheah, S.H. Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro. In Vitro Cell.Dev.Biol.-Animal 53, 435–447 (2017). https://doi.org/10.1007/s11626-016-0126-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11626-016-0126-x

Keywords

Search

Navigation